Dr. Perl discusses results from the phase I CHRYSALIS trial, which investigated gilteritinitib in patients with relapsed/refractory acute myeloid leukemia.
Alexander Perl, MD: The New FLT3 Inhibitor Gilteritinib is “Well-Tolerated” in AML
Recent Articles
FDA Places Clinical Hold on Studies of Allogeneic CAR T-Cell Therapy
The U.S. Food and Drug Administration (FDA) has placed a clinical hold on two phase I trials of gene-edited allogeneic chimeric antigen receptor (CAR)...
Hurricane Harvey Flooding Causes High Levels of Carcinogenic Substance
Flooding from Hurricane Harvey damaged an oil refinery in Houston, Texas, releasing dangerous amounts of the carcinogen benzene into the air. The compound is...
Senate Appropriations Committee Approves New Funding Bill for NIH and Opioid Crisis
On September 7, the Senate Labor, Health and Human Services, and Education Appropriations Subcommittee approved the 2018 Labor, Health and Human Services, Education, and...
Can a Post-AHCT, High-Intensity Exercise Program Improve Quality of Life in Patients With Myeloma?
Patients with myeloma who undergo autologous hematopoietic cell transplantation (AHCT) may experience a decline in health-related quality of life (HRQoL). Although exercise has been...
Fertility Issues in Patients With Inherited Bone Marrow Failure Syndromes
More patients with inherited bone marrow failure syndromes (IBMFS) are surviving to adulthood. As they do, they face barriers to pregnancy. It is still...
Current Issue
September 2017, Volume 3, Issue 11
This issue features a look at efforts to include individuals with intellectual and developmental disabilities in clinical research, our new "How I Treat In Brief" section, and more.
